NCT05074550

Safety Evaluation Study for Patients With Polycythemia Vera

Phase I, Open-Label, Multicentre, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of A Single Intravenous PPMX-T003 in Polycythemia Vera

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 6 (estimated)
• Sponsor: Perseus Proteomics Inc. · Industry
• Sex: All
• Age: 20 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is PhaseI Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of PPMX-T003 in Polycythemia Vera

Conditions

• Polycythemia Vera

Interventions

Type	Name	Description
DRUG	PPMX-T003	As an observation and evaluation method, for each dose, in principle, inpatient observation is performed for 1 week from the day before administration, and then safety and pharmacodynamic tests are evaluated by visiting the hospital every 2 weeks.

Timeline

• Start date: 2022-08-24
• Primary completion: 2023-08-01
• Completion: 2024-03-31
• First posted: 2021-10-12
• Last updated: 2023-07-24

Locations

3 sites across 1 country: Japan